The rumors are true! I am beyond excited to take on this new adventure as the inaugural chair of the Systems and Computational Biology (SCB) Department at @WeillCornell thread 👇
Train the same AI 3 times. Same behavior, different circuits.
So is a circuit the algorithm—or just one implementation of it?
Meet ACE: a new way to understand AI. It extracts what different wirings share—to explain why AIs grok and to steer LLMs up to 32B 🧵
#NeurIPS2026
So excited to announce Aevius Labs @aeviuslabs, the third startup to spin out of our research lab! The company builds on our research to make medicine computable. Especially proud to see two of our superstar former trainees, @RowlandPettit (CEO) and @MYLu97 (CTO), leading the company.
businesswire.com/news/home/2…
The code of life is written in nucleic acids, but proteins carry out the instructions. New work from @MSKCancerCenter led by the brilliant @LauraCKida introduces sctRNA-seq, a new single-cell assay that defines how cells translate between these languages
biorxiv.org/content/10.64898…
"Is the Bitter Lesson coming to genomic prediction? An untuned tabular foundation model matches or beats specialized methods"
[so: yes]
biorxiv.org/content/10.64898…
Please re-tweet. 🚨 🧬 💻 We're looking for a motivated postdoctoral associate in computational biology to join our lab at Weill Cornell Medicine in New York City and study chromatin remodeling and 3D genome organization. To apply:
barisiclab.weill.cornell.edu…
Latest research from the lab:
nature.com/articles/s41586-0…
How do cancers emerge from healthy tissue? In @Nature today: leukaemia evolving in yearly blood samples up to 15 yrs before AML. First driver by age 20; each new driver multiplies growth 2–3×. A remarkably simple set of mathematical rules recapitulate it.
nature.com/articles/s41586-0…
WOW!! Incredibly exciting to see this wonderful news! 18 years after we showed that BCL11A was an ideal target for HbF induction, Casgevy received FDA approval, other approaches like post-transcriptional silencing of BCL11A have shown clinical success, and now we have these results from @BeamTx! 👏👏
1/🚨WOW! Beam Therapeutics has announced positive topline results from its BEACON Phase 1/2 study aimed to evaluate ristoglogene autogetemcel (risto-cel) - formally known as $BEAM - 101, in sickle cell disease patients (SCD) with severe vaso-occlusive crises (VOCs). Not only did Beam’s BEACON trial successfully achieved its primary efficacy endpoint - freedom from severe Vaso-occlusive Crises (VOCs) for at least 12 consecutive months, the trail also met all of its primary safety endpoints and secondary endpoints - including freedom from inpatient hospitalization for severe VOCs during a period of 12 consecutive months. These outstanding results supports Beam’s planned U.S. Biologics License Application (BLA) submission to the U.S FDA for risto-cel, which is expected as early as Year-End 2026 - making it Beam’s first potential commercial product in the market.
Reminder: Abstracts are due tomorrow (Nov 10) for the upcoming Keystone Symposium on 'Somatic Mosaicism'. We have an exciting line-up of speakers, and we will be selecting more from the abstracts! @nlbigas@GenomeDoctorkeystonesymposia.org/confere…
Our bodies are colonized by trillions of viruses that we live with in homeostasis. The most diverse and abundant of these viral families are anelloviruses. A new paper from us at @MSKCancerCenter explores what happens after we *all* have been infected
biorxiv.org/content/10.64898… 1/n
Excited to share Seurat v6 and scSLIDE!
Single-cell studies usually compare cells, but scSLIDE lets us compare *samples*. Instead of forcing patients into case/control groups, we can model sample-level variation.
Paper: cell.com/cell/abstract/S0092…
Software: satijalab.org/seurat
Delighted to share our new work in @CellStemCell! Transient epigenome editing durably silences genes in human 🩸 stem cells and mature progeny, without changing 🧬. Congrats to @lrbzldz & our collaborators!
cell.com/cell-stem-cell/full…